Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Whole-Body Irradiation 14Mycophenolic Acid 14fludarabine phosphate 13Cyclophosphamide 13Cytarabine 11Methotrexate 9Granulocyte Colony-Stimulating Factor 9Filgrastim 9Cyclosporine 8Peripheral Blood Stem Cell Transplantation 7Vincristine 6Thiotepa 6Tacrolimus 6Dexamethasone 6Cord Blood Stem Cell Transplantation 6merphos 5fludarabine 5Mitoxantrone 5Clofarabine 5Calcium Dobesilate 5Busulfan 5Mercaptopurine 4Melphalan 4Leucovorin 4Cladribine 4pegaspargase 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Specimen Handling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Biphenotypic, Acute × Acyclovir × Clear all
NCT00061945 2022-05-03

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
302 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡